Ascletis Pharma Inc. (1672.HK) stock price, financials & research

Regular session · HKT · Market data may be delayed.

Company profile

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.

Industry: Biotechnology
Sector: Healthcare
Headquarters: CN
CEO: Jinzi J. Wu
Listed since: Aug 1, 2018
Employees: 202

Market position

52-week range

Current HK$9.875

HK$7.95HK$19.86

Open: HK$9.875
Previous close: HK$9.61
Volume: 0; 0× average
Average volume: 2.63M; Average daily volume
Market cap: 10.35B HKD
Beta: 0.38; Market reference 1
50-day average: HK$10.0022; -1.27% below average
200-day average: HK$13.506; -26.88% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 8.51B CNY
P/E (TTM): -22.8×
P/B (TTM): 4.3×
P/S (TTM): 4,376.06×
EV / EBITDA: -18.04×
Earnings yield: -3.62%
Free cash flow yield: -3.33%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 25.99%
Operating margin: -23853.94%
Net margin: -17745.56%
Return on equity: -18.60%
Return on assets: -17.41%
Return on invested capital: -24.90%

Financial health

Debt / equity: 0×
Current ratio: 15.05×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

2.03M CNY+58.07%

Operating income

−483.76M CNY-63.75%

Net income

−359.88M CNY-19.59%

Metric (CNY)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	2.03M CNY	1.28M CNY	56.6M CNY	54.09M CNY	76.88M CNY
Cost of goods sold	1.5M CNY	548K CNY	30.61M CNY	78.78M CNY	37.7M CNY
Gross profit	527K CNY	735K CNY	25.99M CNY	−24.69M CNY	39.17M CNY
Research and development	409.05M CNY	302.39M CNY	216.78M CNY	267.1M CNY	213.32M CNY
Selling, general, and administrative	75.23M CNY	101.74M CNY	62.96M CNY	32.41M CNY	37.36M CNY
Operating expenses	484.29M CNY	296.15M CNY	150.29M CNY	319.29M CNY	264.14M CNY
Interest income	65.68M CNY	91.99M CNY	99.28M CNY	44.16M CNY	22.51M CNY
Interest expense	164K CNY	—	144K CNY	157K CNY	125K CNY
Depreciation and amortization	12.89M CNY	14.18M CNY	18.48M CNY	30.19M CNY	29.55M CNY
Operating income	−483.76M CNY	−295.42M CNY	−300.21M CNY	−343.98M CNY	−224.97M CNY
Net income	−359.88M CNY	−300.94M CNY	−144.72M CNY	−314.84M CNY	−199.02M CNY